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Dengue/Dengue Hemorrhagic Fever:
The Emergence of a Global Health Problem
Dengue and dengue hemorrhagic fever (DHF) are
caused by one of four closely related, but antigeni-
cally distinct, virus serotypes (DEN-1, DEN-2, DEN-
3, and DEN-4), of the genus Flavivirus (1). Infection
with one of these serotypes does not provide cross-
protective immunity, so persons living in a dengue-
endemic area can have four dengue infections during
their lifetimes. Dengue is primarily an urban dis-
ease of the tropics, and the viruses that cause it are
maintained in a cycle that involves humans and
Aedes aegypti, a domestic, day-biting mosquito that
prefers to feed on humans. Infection with a dengue
virus serotype can produce a spectrum of clinical
illness, ranging from a nonspecific viral syndrome to
severe and fatal hemorrhagic disease. Important
risk factors for DHF include the strain and serotype
of the virus involved, as well as the age, immune
status, and genetic predisposition of the patient.
The first reported epidemics of dengue fever oc-
curred in 1779-1780 in Asia, Africa, and North Amer-
ica; the near simultaneous occurrence of outbreaks
on three continents indicates that these viruses and
their mosquito vector have had a worldwide distri-
bution in the tropics for more than 200 years. During
most of this time, dengue fever was considered a
benign, nonfatal disease of visitors to the tropics.
Generally, there were long intervals (10-40 years)
between major epidemics, mainly because the vi-
ruses and their mosquito vector could only be trans-
ported between population centers by sailing
vessels.
A global pandemic of dengue begun in Southeast
Asia after World War II and has intensified during
the last 15 years. Epidemics caused by multiple
serotypes (hyperendemicity) are more frequent, the
geographic distribution of dengue viruses has ex-
panded, and DHF has emerged in the Pacific region
and the Americas (1,2). In Southeast Asia, epidemic
DHF first appeared in the 1950s, but by 1975 it had
become a leading cause of hospitalization and death
among children in many countries. In the 1980s,
DHF began a second expansion into Asia when Sri
Lanka, India, and the Maldive Islands had their first
major DHF epidemics; Pakistan first reported an
epidemic of dengue fever in 1994. The recent epidem-
ics in Sri Lanka and India were associated with
multiple dengue virus serotypes, but DEN-3 was
predominant and was genetically distinct from
DEN-3 viruses previously isolated from infected per-
sons in those countries (3).
After an absence of 35 years, epidemic dengue
fever occurred in both Taiwan and the People’s Re-
public of China in the 1980s. The People’s Republic
of China had a series of epidemics caused by all four
serotypes, and its first major epidemic of DHF,
caused by DEN-2, was reported on Hainan Island in
1985 (4). Singapore also had a resurgence of den-
gue/DHF from 1990 to 1994 after a successful control
program had prevented significant transmission for
over 20 years (5). In other countries of Asia where
DHF is endemic, the epidemics have become pro-
gressively larger in the last 15 years.
In the Pacific, dengue viruses were reintroduced
in the early 1970s after an absence of more than 25
years. Epidemic activity caused by all four serotypes
has intensified in recent years with major epidemics
of DHF on several islands (6).
Despite poor surveillance for dengue in Africa, we
know that epidemic dengue fever caused by all four
serotypes has increased dramatically since 1980.
Most activity has occurred in East Africa, and major
epidemics were reported for the first time in the
Seychelles (1977), Kenya (1982, DEN-2), Mozam-
bique (1985, DEN-3), Djibouti (1991-92, DEN-2),
Somalia (1982, 1993, DEN-2), and Saudi Arabia
(1994, DEN-2) (1,6, CDC, unpublished data). Epi-
demic DHF has been reported in neither Africa nor
the Middle East, but sporadic cases clinically com-
patible with DHF have been reported from Mozam-
bique, Djibouti, and Saudi Arabia (CDC,
unpublished data).
The emergence of dengue/DHF as a major public
health problem has been most dramatic in the
American region. In an effort to prevent urban yel-
low fever, which is also transmitted by Ae. aegypti,
the Pan American Health Organization organized a
campaign that eradicated Ae. aegypti from most
Central and South American countries in the 1950s
and 1960s. As a result, epidemic dengue occurred
only sporadically in some Caribbean islands during
this period. The Ae. aegypti eradication program,
which was officially discontinued in the United
States in 1970, gradually eroded elsewhere, and this
species began to reinfest countries from which it had
been eradicated. In 1995, the geographic distribu-
tion of Ae. aegypti was similar to its distribution
before the eradication program (Figure 1). 
In 1970, only DEN-2 virus was present in the
Americas, although DEN-3 may have had a focal
distribution in Colombia and Puerto Rico (7). In
1977, DEN-1 was introduced and caused major epi-
demics throughout the region over a 16-year period
(7). DEN-4 was introduced in 1981 and caused simi-
lar widespread epidemics (7). Also in 1981, a new
strain of DEN-2 from Southeast Asia caused the first
major DHF epidemic in the Americas (Cuba) (7).
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and has caused outbreaks of DHF in Venezuela,
Colombia, Brazil, French Guiana, Suriname, and
Puerto Rico. By 1995, 14 countries in the American
region had reported confirmed DHF cases (Figure 2),
and DHF is endemic in many of these countries.
DEN-3 virus recently reappeared in the Americas
after an absence of 16 years. This serotype was first
detected in association with a 1994 dengue/DHF
epidemic in Nicaragua (8). Almost simultaneously,
DEN-3 was confirmed in Panama and, in early 1995,
in Costa Rica (8, CDC, unpublished data). In Nica-
ragua, considerable numbers of DHF were associ-
ated with the epidemic, which was apparently
caused by DEN-3. In Panama and Costa Rica, the
cases were classic dengue fever.
Viral envelope gene sequence data from the DEN-
3 strains isolated from Panama and Nicaragua have
shown that this new American DEN-3 virus strain
was likely a recent introduction from Asia since it is
genetically distinct from the DEN-3 strain found
previously in the Americas, but is identical to the
DEN-3 virus serotype that caused major DHF epi-
demics in Sri Lanka and India in the 1980s (R.
Lanciotti; unpublished data). The new DEN-3
strain, and the susceptibility of the population in the
American tropics to it, suggests that DEN-3 will
spread rapidly throughout the region and likely will
cause major epidemics of dengue/DHF in the near
future.
In 1995, dengue is the most important mosquito-
borne viral disease affecting humans; its global dis-
tribution is comparable to that of malaria, and an
estimated 2.5 billion people are living in areas at
risk for epidemic transmission (Figure 3). Each year,
tens of millions of cases of dengue fever occur and,
depending on the year, up to hundreds of thousands
of cases of DHF. The case-fatality rate of DHF in
most countries is about 5%: most fatal cases are
among children.
There is a small, but significant, risk for dengue
outbreaks in the continental United States. Two
competent mosquito vectors, Ae. aegypti and Aedes
albopictus, are present and, under certain circum-
stances, each could transmit dengue viruses. This
type of transmission has been detected twice in the
last 15 years in south Texas (1980 and 1986) and has
been associated with dengue epidemics in northern
Mexico (7). Moreover, numerous viruses are intro-
duced annually by travelers returning from tropical
areas where dengue viruses are endemic. From 1977
to 1994, a total of 2,248 suspected cases of imported
dengue were reported in the United States (9, CDC,
unpublished data). Although some specimens col-
lected were not adequate for laboratory diagnosis,
preliminary data indicate that 481 (21%) cases were
confirmed as dengue (9, CDC, unpublished data).
Many more cases probably go unreported each year
because surveillance in the United States is passive
and relies on physicians to recognize the disease,
inquire about the patient’s travel history, obtain
proper diagnostic samples, and report the case.
These data underscore the fact that southern Texas
and the southeastern United States, where Ae.
aegypti is found, are at risk for dengue transmission
and sporadic outbreaks.
The reasons for this dramatic global emergence
of dengue/DHF as a major public health problem are
complex and not well understood (10). However,
several important factors can be identified. First,
effective mosquito control is virtually nonexistent in
most dengue-endemic countries. Considerable em-
phasis for the past 20 years has been placed on
ultra-low-volume insecticide space sprays for adult
mosquito control, a relatively ineffective approach
for controlling Ae. aegypti. Second, major global
demographic changes have occurred, the most im-
portant of which have been uncontrolled urbaniza-
tion and concurrent population growth. These
demographic changes have resulted in substandard
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Figure 2. American countries with laboratory-
confirmed hemorrhagic fever (shaded areas), prior to
1981 and from 1981 to 1995.
1970 1995
Figure 1. Distribution of Aedes aegypti (shaded areas)
in the Americas in 1970, at the end of the mosquito
eradication program, and in 1995.
Dispatches
Emerging Infectious Diseases 56 Vol. 1, No. 2 — April-June 1995housing and inadequate water, sewer, and waste
management systems, all of which increase
Ae. aegypti population densities and facilitate
transmission of Ae. aegypti-borne disease. Third,
increased travel by airplane provides the ideal
mechanism for transporting dengue viruses be-
tween population centers of the tropics, resulting in
a constant exchange of dengue viruses and other
pathogens. Lastly, in most countries the public
health infrastructure has deteriorated. Limited fi-
nancial and human resources and competing priori-
ties have resulted in a “crisis mentality” with
emphasis on implementing so-called emergency con-
trol methods in response to epidemics rather than
on developing programs to prevent epidemic trans-
mission. This approach has been particularly detri-
mental to dengue control because, in most countries,
surveillance is very inadequate; the system to detect
increased transmission normally relies on reports by
local physicians who often do not consider dengue in
their diagnoses. As a result, an epidemic has often
reached or passed the peak of transmission before it
is detected.
No dengue vaccine is available. Recently, how-
ever, attenuated candidate vaccine viruses have
been developed in Thailand. These vaccines are safe
and immunogenic when given in various formula-
tions, including a quadrivalent vaccine for all four
dengue virus serotypes. Unfortunately, efficacy tri-
als in human volunteers have yet to be initiated.
Research is also being conducted to develop second-
generation recombinant vaccine viruses; the Thai-
land attenuated viruses are used as a template.
However, an effective dengue vaccine for public use
will not be available for 5 to 10 years. 
Prospects for reversing the recent trend of in-
creased epidemic activity and geographic expansion
of dengue are not promising. New dengue virus
strains and serotypes will likely continue to be intro-
duced into many areas where the population densi-
ties of Ae. aegypti are at high levels. With no new
mosquito control technology available, in recent
years public health authorities have emphasized
disease prevention and mosquito control through
community efforts to reduce larval breeding sources
(11). Although this approach will probably be effec-
tive in the long run, it is unlikely to impact disease
transmission in the near future. We must, therefore,
develop improved, proactive, laboratory-based sur-
veillance systems that can provide early warning of
an impending dengue epidemic. At the very least,
surveillance results can alert the public to take
action and physicians to diagnose and properly treat
dengue/DHF cases.
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Figure 3. World distribution of dengue viruses and their
mosquito vector, Aedes aegypti, in 1995.
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